Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Sarcoma 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

entrectinib 2venetoclax 1trametinib 1tazemetostat 1sodium thiosulfate 1selpercatinib 1ripretinib 1repotrectinib 1pirtobrutinib 1pembrolizumab 1nirogacestat 1larotrectinib 1dabrafenib 1avapritinib 1atezolizumab 1Taxes 1Specimen Handling 1Rituximab 1Restraint, Physical 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × pirtobrutinib × Sarcoma × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡